Hiroshi Nanjo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hiroshi Nanjo has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
- Yusuke Sato
Division of Esophageal Surgery, Akita University Hospital, Akita, Japan
5 shared publications - Kazuhiro Imai
Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita, Japan
4 shared publications - Yoshihiro Minamiya
Department of Thoracic Surgery, Akita University Graduate School of Medicine, Akita 010-8543, Japan
4 shared publications - Akiyuki Wakita
Department of Thoracic Surgery, Akita University Graduate School of Medicine , 1-1-1 Hondo, Akita 010-8543
3 shared publications - Hiroyuki Shibata
Department of Clinical Oncology, Graduate School of Medicine, Akita University, Akita, Japan
3 shared publications - Kyoko Nomura
Department of Environmental Health Science and Public Health, Akita University Graduate School of Medicine
3 shared publications
Latest Publications
- 6 November 2026
- Published by Springer Nature in Virchows Archiv
- p. 1-11
A clinicopathological and molecular analysis of intrasalivary thymic-like neoplasms—An unestablished salivary gland tumor entity
Salivary gland tumors with thymic-like differentiation have recently been recognized as a distinct pathological entity, although their origin is unknown and their defining features remain incompletely characterized. These lesions encompass carcinoma showing thymus-like elements/differentiation, as well as thymus-like lesions, whose malignant potential remains uncertain. In this study, we collected 9 cases of salivary gland tumors with thymic-like differentiation and investigated their clinicopathological, immunohistochemical, and molecular characteristics. Thymic-like differentiation was defined as tumor cell proliferation with nested, trabecular, and solid architecture, the presence of abundant lymphocytic infiltrates, and the expression of CD5 and CD117/c-KIT. All tumors arose in the parotid gland, and the median age of the patients was 63 years. Histologically, 8 tumors were frankly malignant with marked nuclear atypia, among which benign components were observed in 3 cases. One case consisted solely of a benign component. Although Hassall’s corpuscle-like structures were noted in 2 cases, no definitive thymic remnants were identified in any of the cases. Amyloid deposition containing CK19 and CK5 as its components was observed in 3 cases. Targeted DNA sequencing revealed alterations primarily in tumor suppressor genes including PTEN, RB1, and TP53 in the malignant components, but no variants were detected in the benign components. These tumors comprise both malignant carcinomatous and benign components. We propose designating these tumors collectively as “intrasalivary thymic-like neoplasms.”
- 6 November 2026
- Published by Springer Nature in Virchows Archiv
- p. 1-11
A clinicopathological and molecular analysis of intrasalivary thymic-like neoplasms—An unestablished salivary gland tumor entity
Salivary gland tumors with thymic-like differentiation have recently been recognized as a distinct pathological entity, although their origin is unknown and their defining features remain incompletely characterized. These lesions encompass carcinoma showing thymus-like elements/differentiation, as well as thymus-like lesions, whose malignant potential remains uncertain. In this study, we collected 9 cases of salivary gland tumors with thymic-like differentiation and investigated their clinicopathological, immunohistochemical, and molecular characteristics. Thymic-like differentiation was defined as tumor cell proliferation with nested, trabecular, and solid architecture, the presence of abundant lymphocytic infiltrates, and the expression of CD5 and CD117/c-KIT. All tumors arose in the parotid gland, and the median age of the patients was 63 years. Histologically, 8 tumors were frankly malignant with marked nuclear atypia, among which benign components were observed in 3 cases. One case consisted solely of a benign component. Although Hassall’s corpuscle-like structures were noted in 2 cases, no definitive thymic remnants were identified in any of the cases. Amyloid deposition containing CK19 and CK5 as its components was observed in 3 cases. Targeted DNA sequencing revealed alterations primarily in tumor suppressor genes including PTEN, RB1, and TP53 in the malignant components, but no variants were detected in the benign components. These tumors comprise both malignant carcinomatous and benign components. We propose designating these tumors collectively as “intrasalivary thymic-like neoplasms.”
- 7 October 2026
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
Ex Vivo Comparative Experiments Demonstrating the Ablation Effect of a Temperature‐Controlled Radiofrequency Ablation System
Background: A temperature‐controlled radiofrequency ablation (TC‐RFA) system has been introduced to reduce excessive thermal damage and enable safer treatment. However, the ablation effect of this system remains to be fully elucidated. Therefore, this ex vivo study aimed to directly compare the ablation characteristics of the TC‐RFA with those of a power‐controlled RFA (PC‐RFA). Methods: Pig liver specimens were used. The TC‐RFA using all four probe types and the PC‐RFA were performed step‐by‐step to macroscopically evaluate the ablation area and speed. Linear regression models with interaction terms were used to compare changes in ablation dimensions over time between RFA devices and probes. Results: The TC‐RFA produced different short‐axis ablation diameters depending on the probe even at the same temperature setting and generated an ablation effect at an earlier time, with substantially less change in ablation dimensions over time than the PC‐RFA. In contrast, the PC‐RFA had the slowest onset, but its ablation area continued to increase in width and depth with longer ablation durations. These differences in ablation behavior over time were statistically significant (Holm‐adjusted p < 0.001). Conclusions: In these exploratory ex vivo experiments, the TC‐RFA system produced earlier and more consistent ablation effects over time than the PC‐RFA system.
- 7 October 2026
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
Ex Vivo Comparative Experiments Demonstrating the Ablation Effect of a Temperature‐Controlled Radiofrequency Ablation System
Background: A temperature‐controlled radiofrequency ablation (TC‐RFA) system has been introduced to reduce excessive thermal damage and enable safer treatment. However, the ablation effect of this system remains to be fully elucidated. Therefore, this ex vivo study aimed to directly compare the ablation characteristics of the TC‐RFA with those of a power‐controlled RFA (PC‐RFA). Methods: Pig liver specimens were used. The TC‐RFA using all four probe types and the PC‐RFA were performed step‐by‐step to macroscopically evaluate the ablation area and speed. Linear regression models with interaction terms were used to compare changes in ablation dimensions over time between RFA devices and probes. Results: The TC‐RFA produced different short‐axis ablation diameters depending on the probe even at the same temperature setting and generated an ablation effect at an earlier time, with substantially less change in ablation dimensions over time than the PC‐RFA. In contrast, the PC‐RFA had the slowest onset, but its ablation area continued to increase in width and depth with longer ablation durations. These differences in ablation behavior over time were statistically significant (Holm‐adjusted p < 0.001). Conclusions: In these exploratory ex vivo experiments, the TC‐RFA system produced earlier and more consistent ablation effects over time than the PC‐RFA system.
- Open Access
- 31 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10621
Inhibition of Fatty Acid-Binding Protein 4 Limits High-Fat-Diet-Associated Prostate Tumorigenesis and Progression in TRAMP Mice
Fatty acid-binding protein 4 (FABP4) is an important adipokine associated with inflammatory responses and metabolic regulation. Although a high-fat diet (HF) and/or HF-mediated obesity have been clearly linked to the progression of prostate cancer, with FABP4 potentially playing a critical role in this relationship, the mechanisms by which FABP4 facilitates this interaction remain unclear. After generating FABP4 knockout (FABP4−/−) transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, it was found that FABP4−/− TRAMP mice presented significantly ameliorated prostate tumorigenesis and tumor progression along with decreased body weight, protumorigenic cytokine secretion, and pan-amino acid synthesis when compared to TRAMP mice under the HF condition. Additionally, treatment with BMS309403—a chemical inhibitor of FABP4—was observed to abrogate the HF-mediated TRAMP tumor progression, along with reductions in body weight and cytokine production. Thus, FABP4 plays an essential role in the progression of HF-mediated prostate cancer through the modulation of metabolic and inflammatory pathways, providing a potential therapeutic target for prostate cancer.
- 31 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10621
Open AccessInhibition of Fatty Acid-Binding Protein 4 Limits High-Fat-Diet-Associated Prostate Tumorigenesis and Progression in TRAMP Mice
Fatty acid-binding protein 4 (FABP4) is an important adipokine associated with inflammatory responses and metabolic regulation. Although a high-fat diet (HF) and/or HF-mediated obesity have been clearly linked to the progression of prostate cancer, with FABP4 potentially playing a critical role in this relationship, the mechanisms by which FABP4 facilitates this interaction remain unclear. After generating FABP4 knockout (FABP4−/−) transgenic adenocarcinoma of the mouse prostate (TRAMP) mice, it was found that FABP4−/− TRAMP mice presented significantly ameliorated prostate tumorigenesis and tumor progression along with decreased body weight, protumorigenic cytokine secretion, and pan-amino acid synthesis when compared to TRAMP mice under the HF condition. Additionally, treatment with BMS309403—a chemical inhibitor of FABP4—was observed to abrogate the HF-mediated TRAMP tumor progression, along with reductions in body weight and cytokine production. Thus, FABP4 plays an essential role in the progression of HF-mediated prostate cancer through the modulation of metabolic and inflammatory pathways, providing a potential therapeutic target for prostate cancer.
- Open Access
Evaluation of Grading Estrogen Receptors in Breast Cancer Using Fully Automated Rapid Immunohistochemistry Based on Alternating-Current Electric Field Technology
Background: Immunohistochemistry (IHC) is crucial for determining cancer treatments. We previously developed a rapid IHC method and have now developed a fully automated rapid IHC stainer (R-Auto). This study aimed to evaluate the clinical reliability of the R-Auto protocol for staining estrogen receptors (ERs) in breast cancer specimens and evaluate the staining performance. Methods: Between January 2015 and June 2020, 188 surgical specimens collected from breast cancer patients treated at our hospital were evaluated via ER staining using R-Auto, conventional manual IHC, and a commercial autostainer. The specimens were scored using Allred scores, after which the staining results were compared between R-Auto and conventional IHC or the commercial autostainer. Weighted kappa coefficients and AC1 statistics were used to assess the agreement between the methods. Results: The AC1 statistic for comparison between R-Auto and conventional IHC was 0.9490 (0.9139–0.9841), with a 95.7% agreement rate, and that for comparison between R-Auto and the commercial autostainer was 0.9095 (0.8620–0.9570), with a 92.6% agreement. There was, thus, substantial agreement between R-Auto and both conventional IHC and the commercial autostainer. However, R-Auto shortened the time required for IHC from 209 min with conventional IHC to 121 min. Conclusions: R-Auto enables a good staining performance in a shorter time with less effort.
Open AccessEvaluation of Grading Estrogen Receptors in Breast Cancer Using Fully Automated Rapid Immunohistochemistry Based on Alternating-Current Electric Field Technology
Background: Immunohistochemistry (IHC) is crucial for determining cancer treatments. We previously developed a rapid IHC method and have now developed a fully automated rapid IHC stainer (R-Auto). This study aimed to evaluate the clinical reliability of the R-Auto protocol for staining estrogen receptors (ERs) in breast cancer specimens and evaluate the staining performance. Methods: Between January 2015 and June 2020, 188 surgical specimens collected from breast cancer patients treated at our hospital were evaluated via ER staining using R-Auto, conventional manual IHC, and a commercial autostainer. The specimens were scored using Allred scores, after which the staining results were compared between R-Auto and conventional IHC or the commercial autostainer. Weighted kappa coefficients and AC1 statistics were used to assess the agreement between the methods. Results: The AC1 statistic for comparison between R-Auto and conventional IHC was 0.9490 (0.9139–0.9841), with a 95.7% agreement rate, and that for comparison between R-Auto and the commercial autostainer was 0.9095 (0.8620–0.9570), with a 92.6% agreement. There was, thus, substantial agreement between R-Auto and both conventional IHC and the commercial autostainer. However, R-Auto shortened the time required for IHC from 209 min with conventional IHC to 121 min. Conclusions: R-Auto enables a good staining performance in a shorter time with less effort.
- Open Access
- 1 January 2025
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 11 (1) , cr.25-0537
Multiple Pulmonary Cavernous Hemangioma: A Case Report
INTRODUCTION: Pulmonary cavernous hemangioma (PCH) is extremely rare and, due to the lack of specific radiological characteristics, is often misdiagnosed as other pulmonary diseases, including metastatic tumors. Here, we report a case of multiple PCH lesions with concomitant hepatic cavernous hemangioma (HCH), emphasizing the diagnostic implications of imaging findings.CASE PRESENTATION: A 57-year-old man presented with fever. CT revealed numerous well-circumscribed pulmonary nodules and multiple low-density hepatic lesions. Dynamic contrast-enhanced CT demonstrated mild, nonspecific enhancement of the pulmonary nodules, whereas the hepatic lesions showed enhancement from the center to the periphery. Serum tumor markers were within normal limits, and PET-CT revealed no abnormal fluorodeoxyglucose uptake in any of the lesions. Although the hepatic lesions appeared suggestive of hemangioma on imaging, the possibility of malignancy, such as hepatic angiosarcoma and its pulmonary metastases, could not be completely ruled out. Therefore, both hepatic and pulmonary biopsies were performed, and histopathological examination confirmed cavernous hemangioma in both organs.CONCLUSIONS: PCH is a rare benign tumor lacking distinctive imaging characteristics; therefore, differentiation from metastatic pulmonary tumors is often challenging and represents a key diagnostic issue. Although definitive diagnosis currently relies on surgical biopsy, combining suggestive imaging findings—such as the presence of microcalcifications within nodules and the absence of fluorodeoxyglucose uptake on PET-CT—may help avoid unnecessary invasive procedures.
- 1 January 2025
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 11 (1) , cr.25-0537
Open AccessMultiple Pulmonary Cavernous Hemangioma: A Case Report
INTRODUCTION: Pulmonary cavernous hemangioma (PCH) is extremely rare and, due to the lack of specific radiological characteristics, is often misdiagnosed as other pulmonary diseases, including metastatic tumors. Here, we report a case of multiple PCH lesions with concomitant hepatic cavernous hemangioma (HCH), emphasizing the diagnostic implications of imaging findings.CASE PRESENTATION: A 57-year-old man presented with fever. CT revealed numerous well-circumscribed pulmonary nodules and multiple low-density hepatic lesions. Dynamic contrast-enhanced CT demonstrated mild, nonspecific enhancement of the pulmonary nodules, whereas the hepatic lesions showed enhancement from the center to the periphery. Serum tumor markers were within normal limits, and PET-CT revealed no abnormal fluorodeoxyglucose uptake in any of the lesions. Although the hepatic lesions appeared suggestive of hemangioma on imaging, the possibility of malignancy, such as hepatic angiosarcoma and its pulmonary metastases, could not be completely ruled out. Therefore, both hepatic and pulmonary biopsies were performed, and histopathological examination confirmed cavernous hemangioma in both organs.CONCLUSIONS: PCH is a rare benign tumor lacking distinctive imaging characteristics; therefore, differentiation from metastatic pulmonary tumors is often challenging and represents a key diagnostic issue. Although definitive diagnosis currently relies on surgical biopsy, combining suggestive imaging findings—such as the presence of microcalcifications within nodules and the absence of fluorodeoxyglucose uptake on PET-CT—may help avoid unnecessary invasive procedures.
- Open Access
- 31 December 2024
- Published by MDPI AG in Preprints.org
Evaluation of Grading and Estrogen Receptors in Breast Cancer Using a Fully Automated Rapid Immunohistochemistry Based on Alternating Current Electric Field Technology
Background: Immunohistochemistry (IHC) is crucial for determining cancer treatments. We previously developed a rapid IHC method and have now developed a fully automated rapid IHC stainer (R-Auto). The aim of this study was to evaluate the clinical reliability of the R-Auto protocol for staining estrogen receptors (ERs) in breast cancer specimens and evaluated the staining performance. Methods: Between January 2015 and June 2020, 188 surgical specimens collected from breast cancer patients treated at our hospital were evaluated through ER staining using R-Auto, conventional manual (conventional) IHC and a commercial autostainer. The specimens were scored using Allred scores, after which the staining results were compared between R-Auto and the conventional IHC or commercial autostainer. Weighted kappa coefficients and AC1 statistics were used to assess the agreement between methods. Results: The AC1 statistic for comparison between R-Auto and conventional IHC was 0.9490 (0.9139-0.9841) with a 95.7% agreement rate and was 0.9095 (0.8620-0.9570) with a 92.6% agreement rate for comparison between R-Auto and the commercial autostainer. There was thus substantial agreement between R-Auto and both conventional IHC and the commercial autostainer. However, R-Auto shortened the time required for IHC from 209 minutes with conventional IHC to 121 minutes. Conclusions: R-Auto enables good staining performance in a shorter time with less effort.
- 31 December 2024
- Published by MDPI AG in Preprints.org
Open AccessEvaluation of Grading and Estrogen Receptors in Breast Cancer Using a Fully Automated Rapid Immunohistochemistry Based on Alternating Current Electric Field Technology
Background: Immunohistochemistry (IHC) is crucial for determining cancer treatments. We previously developed a rapid IHC method and have now developed a fully automated rapid IHC stainer (R-Auto). The aim of this study was to evaluate the clinical reliability of the R-Auto protocol for staining estrogen receptors (ERs) in breast cancer specimens and evaluated the staining performance. Methods: Between January 2015 and June 2020, 188 surgical specimens collected from breast cancer patients treated at our hospital were evaluated through ER staining using R-Auto, conventional manual (conventional) IHC and a commercial autostainer. The specimens were scored using Allred scores, after which the staining results were compared between R-Auto and the conventional IHC or commercial autostainer. Weighted kappa coefficients and AC1 statistics were used to assess the agreement between methods. Results: The AC1 statistic for comparison between R-Auto and conventional IHC was 0.9490 (0.9139-0.9841) with a 95.7% agreement rate and was 0.9095 (0.8620-0.9570) with a 92.6% agreement rate for comparison between R-Auto and the commercial autostainer. There was thus substantial agreement between R-Auto and both conventional IHC and the commercial autostainer. However, R-Auto shortened the time required for IHC from 209 minutes with conventional IHC to 121 minutes. Conclusions: R-Auto enables good staining performance in a shorter time with less effort.
- Open Access
- 11 November 2023
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (2) , 201-205
Clinical response of pancreatic cancer bearing a germline BRCA2 p.I3169M fs*48 variant for platinum-based drug and PARP inhibitor
Pancreatic cancer is a malignancy with a high mortality rate, accounting for 37 000 people annually in Japan. It is rarely diagnosed in a resectable state, and effective medicines for its advanced stage are scarce. Some pancreatic cancer is hereditary, and ~10% have germline mutations of Breast cancer 1/2 (BRCA1/2). BRCA1/2 are key molecules involved in homologous recombination to repair DNA double-strand break. Platinum-based drugs and poly Adenosine diphosphate ribose (ADP) ribose polymerase inhibitors that induce synthetic lethality would be theoretically effective in patients with loss-of-function mutations in BRCA1/2. Strictly speaking, some discrepancy between the pathogenicity of BRCA1/2 and their drug sensitivity might be expected. Hence, we report that platinum-based anticancer agents and poly ADP ribose polymerase inhibitors were effective against pancreatic cancer bearing BRCA2 p.I3169M fs*48.
- 11 November 2023
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (2) , 201-205
Open AccessClinical response of pancreatic cancer bearing a germline BRCA2 p.I3169M fs*48 variant for platinum-based drug and PARP inhibitor
Pancreatic cancer is a malignancy with a high mortality rate, accounting for 37 000 people annually in Japan. It is rarely diagnosed in a resectable state, and effective medicines for its advanced stage are scarce. Some pancreatic cancer is hereditary, and ~10% have germline mutations of Breast cancer 1/2 (BRCA1/2). BRCA1/2 are key molecules involved in homologous recombination to repair DNA double-strand break. Platinum-based drugs and poly Adenosine diphosphate ribose (ADP) ribose polymerase inhibitors that induce synthetic lethality would be theoretically effective in patients with loss-of-function mutations in BRCA1/2. Strictly speaking, some discrepancy between the pathogenicity of BRCA1/2 and their drug sensitivity might be expected. Hence, we report that platinum-based anticancer agents and poly ADP ribose polymerase inhibitors were effective against pancreatic cancer bearing BRCA2 p.I3169M fs*48.
- Open Access
- 4 May 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (5) , 4724-4735
High TLR6 Expression Status Predicts a More Favorable Prognosis after Esophagectomy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Most so-called “beneficial bacteria” in gut microbiota are Gram-positive, and TLR6 recognizes the peptidoglycan (PGN) present in their cell walls. We hypothesized that a high TLR6 expression status predicts a more favorable prognosis after esophagectomy. We used an ESCC tissue microarray (TMA) to examine TLR6 expression status in ESCC patients and to determine whether TLR6 expression status correlates with prognosis after curative esophagectomy. We also examined whether PGN influences the cell proliferation activity of ESCC lines. Clinical ESCC samples from 177 patients tested for the expression of TLR6 were categorized as 3+ (n = 17), 2+ (n = 48), 1+ (n = 68), or 0 (n = 44). High TLR6 expression (3+ and 2+) correlated with significantly more favorable 5-year overall survival (OS) and disease-specific survival (DSS) after esophagectomy than a lower TLR6 expression (1+ and 0). Univariate and multivariate analyses showed that TLR6 expression status is an independent prognostic factor that affects 5-year OS. PGN significantly inhibited the cell proliferation activity of ESCC lines. This is the first study to show that high TLR6 expression status predicts a more favorable prognosis in locally advanced thoracic ESCC patients after curative esophagectomy. PGN released from “beneficial bacteria” seems to have potential to inhibit the cell proliferation activity of ESCC.
- 4 May 2023
- Published by MDPI AG in Current Oncology
- Vol. 30 (5) , 4724-4735
Open AccessHigh TLR6 Expression Status Predicts a More Favorable Prognosis after Esophagectomy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Most so-called “beneficial bacteria” in gut microbiota are Gram-positive, and TLR6 recognizes the peptidoglycan (PGN) present in their cell walls. We hypothesized that a high TLR6 expression status predicts a more favorable prognosis after esophagectomy. We used an ESCC tissue microarray (TMA) to examine TLR6 expression status in ESCC patients and to determine whether TLR6 expression status correlates with prognosis after curative esophagectomy. We also examined whether PGN influences the cell proliferation activity of ESCC lines. Clinical ESCC samples from 177 patients tested for the expression of TLR6 were categorized as 3+ (n = 17), 2+ (n = 48), 1+ (n = 68), or 0 (n = 44). High TLR6 expression (3+ and 2+) correlated with significantly more favorable 5-year overall survival (OS) and disease-specific survival (DSS) after esophagectomy than a lower TLR6 expression (1+ and 0). Univariate and multivariate analyses showed that TLR6 expression status is an independent prognostic factor that affects 5-year OS. PGN significantly inhibited the cell proliferation activity of ESCC lines. This is the first study to show that high TLR6 expression status predicts a more favorable prognosis in locally advanced thoracic ESCC patients after curative esophagectomy. PGN released from “beneficial bacteria” seems to have potential to inhibit the cell proliferation activity of ESCC.
- 8 December 2022
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 53 (3) , 270-274
Lymph-node metastasis from gastric adenocarcinoma in a patient bearing a germ line missense variantMSH2c.1808A > T (Asp603Val) responds to the immune checkpoint inhibitor pembrolizumab
We report the sensitivity of immune checkpoint inhibitors for tumors developing in a patient bearing the MSH2 c.1808A > T (Asp603Val) variant belonging to a pedigree of Lynch syndrome. This variant was previously thought to be of unknown significance, but we recently found that this missense mutation was likely pathogenic. At that time, there were no active members with malignancies that could be treated with chemotherapy. Thereafter, an 81-year-old woman bearing this variant, who was a cousin of the proband of this family, had multiple lymph node metastases from her resected gastric cancer. An immune checkpoint inhibitor, pembrolizumab, an anti-PD-1 antibody, was used to treat these tumors. After 3 months of treatment, almost all tumors disappeared, and elevated CA19–9 levels normalized. She survives over 15 months safely. It was indicated that the tumors bearing this germline variant were sensitive to pembrolizumab. This observation suggests that an MSH2 c.1808A > T (Asp603Val) variant induces mismatch repair deficiency, resulting in sensitization to immune checkpoint inhibition.
- 8 December 2022
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 53 (3) , 270-274
Lymph-node metastasis from gastric adenocarcinoma in a patient bearing a germ line missense variantMSH2c.1808A > T (Asp603Val) responds to the immune checkpoint inhibitor pembrolizumab
We report the sensitivity of immune checkpoint inhibitors for tumors developing in a patient bearing the MSH2 c.1808A > T (Asp603Val) variant belonging to a pedigree of Lynch syndrome. This variant was previously thought to be of unknown significance, but we recently found that this missense mutation was likely pathogenic. At that time, there were no active members with malignancies that could be treated with chemotherapy. Thereafter, an 81-year-old woman bearing this variant, who was a cousin of the proband of this family, had multiple lymph node metastases from her resected gastric cancer. An immune checkpoint inhibitor, pembrolizumab, an anti-PD-1 antibody, was used to treat these tumors. After 3 months of treatment, almost all tumors disappeared, and elevated CA19–9 levels normalized. She survives over 15 months safely. It was indicated that the tumors bearing this germline variant were sensitive to pembrolizumab. This observation suggests that an MSH2 c.1808A > T (Asp603Val) variant induces mismatch repair deficiency, resulting in sensitization to immune checkpoint inhibition.
- 1 March 2021
- Published by Elsevier in Human Pathology
- Vol. 109, 31-36
Detection of MED12 mutations in mesenchymal components of uterine adenomyomas
- 1 March 2021
- Published by Elsevier in Human Pathology
- Vol. 109, 31-36
Detection of MED12 mutations in mesenchymal components of uterine adenomyomas